TriangleHEALTH PROFESSIONAL · SOURCE READING
Watchful waiting for asymptomatic patients
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Because relapse may occur many years after treatment, even in patients who have achieved complete responses, deferred treatment (i.e., watchful waiting until the patient becomes symptomatic before initiating treatment) can be considered.[2,6-8] The Follicular Lymphoma International Prognostic Index (FLIPI) and the revised FLIPI-2 can predict progression-free survival (PFS) and overall survival (OS), but the scores cannot be used to establish the need for therapy in asymptomatic patients.[9,10]
Evidence (watchful waiting):
Three randomized trials compared watchful waiting with immediate chemotherapy.[7,11]; [12][Level of evidence A1]
Source links and citations
Three randomized trials compared watchful waiting with immediate chemotherapy.[7,11]; [12][Level of evidence A1]
All three trials showed no difference in cause-specific survival or OS.
Three randomized trials compared watchful waiting with immediate chemotherapy.[7,11]; [12][Level of evidence A1]
For patients randomly assigned to watchful waiting, the median time to require therapy was 2 to 3 years. One-third of patients undergoing watchful waiting never required treatment (one-half died of other causes and the other half remained progression free after 10 years).
A selected group of 107 patients with advanced-stage follicular lymphoma were managed with initial watchful waiting; subsequent therapy was delayed for a median of 55 months. These patients achieved equivalent freedom from treatment failure and OS compared with a similar cohort treated immediately with rituximab.[13][Level of evidence C2] This implies that watchful waiting remains a relevant approach even in the rituximab era.
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Independent clinical review pending · Not medical advice